U.S. market Closed. Opens in 23 hours 46 minutes

TXG | 10x Genomics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for TXG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable.

Valuation (19%)

Company Industry
P/E Ratio (TTM) -9.29 18.43
PEG Ratio (TTM) -0.38 1.94
P/S Ratio (TTM) 2.70 6.56
P/B Ratio (TTM) 2.35 5.29
P/FCF Ratio (TTM) 67.87 18.13
Price to 5YR AVG Earnings Ratio -6.80 107.44
Price to 5YR AVG FCF Ratio -13.77 45.92

Profitability (0%)

Company Industry
ROA (TTM) -19.47% -0.54%
ROE (TTM) -25.12% 12.91%
Net Profit Margin (TTM) -28.99% 0.57%
ROIC 5YR AVG -36.74% 10.30%

Growth (43%)

4QTR AVG 3YR AVG 5YR AVG
EPS 17.10% -130.21% -123.09%
Revenue 1.01% 51.24% 35.76%
Net Income 16.83% -491.73% -342.80%
Cash Flow 94.28% -164.59% -99.24%

Health (60%)

Company Industry
Current Ratio (TTM) 4.90 2.80
Quick Ratio (TTM) 4.12 2.69
D/E Ratio (TTM) 0.01 0.73
Interest Coverage (TTM) -14,852.50 2.80
Piotroski F-Score 3 5
Altman Z-Score 3.28 9.33
LTL to 5YR AVG FCF -1.36 2.40
Shares Outstanding Growth 5YR AVG 73.16% 23.77%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙